Catalog No.
DHG47801
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Protein-tyrosine kinase 7, Inactive tyrosine-protein kinase 7, CCK4, PTK7, Colon carcinoma kinase 4, Tyrosine-protein kinase-like 7, CCK-4, Pseudo tyrosine kinase receptor 7
Concentration
1.11 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q13308
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
PF-06523435, hu24, Anti-PTK7 ADC, PF-06647020, PTK7-ADC, CAS: 1869928-62-0
Clone ID
Cofetuzumab
A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer., PMID:40086026
Protein Tyrosine Kinase 7 (PTK7) in Breast Cancer: A Retrospective Analysis of Tumour Expression and Association with Clinical Outcome., PMID:39335176
MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors., PMID:37352387
Multiomics characterization implicates PTK7 in ovarian cancer EMT and cell plasticity and offers strategies for therapeutic intervention., PMID:35977930
Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer., PMID:35551360
Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic., PMID:35267507
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors., PMID:34083232
For research use only. Not for human or drug use.
